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M2a macrophageIL-34 is a challenging cytokine sharing functional similarities withM-CSF throughM-CSFR activation. It also plays
a singular role that has recently been explained in the brain, through a binding to the receptor protein tyrosine
phosphatase RPTPβ/ζ. The aim of this paper was to look for alternative binding of IL-34 on other cell types.
Myeloid cells (HL-60, U-937, THP-1) were used as cells intrinsically expressing M-CSFR, and M-CSFR was
expressed in TF-1 and HEK293 cells. IL-34 binding was studied by Scatchard and binding inhibition assays,
using 125I-radiolabelled cytokines, and surface plasmon resonance. M-CSFR activation was analysed by Western
blot after glycosaminoglycans abrasion, syndecan-1 overexpression or repression and addition of a blocking
anti-syndecan antibody. M-CSF and IL-34 induced different patterns of M-CSFR phosphorylations, suggesting
the existence of alternative binding for IL-34. Binding experiments and chondroitinase treatment conﬁrmed
low afﬁnity binding to chondroitin sulphate chains on cells lacking both M-CSFR and RPTPβ/ζ. Amongst the
proteoglycans with chondroitin sulphate chains, syndecan-1 was able to modulate the IL-34-induced M-CSFR
signalling pathways. Interestingly, IL-34 induced the migration of syndecan-1 expressing cells. Indeed, IL-34
signiﬁcantly increased themigration of THP-1 andM2amacrophages thatwas inhibited by addition of a blocking
anti-syndecan-1 antibody. This paper provides evidence of alternative binding of IL-34 to chondroitin sulphates
and syndecan-1 at the cell surface that modulates M-CSFR activation. In addition, IL-34-induced myeloid cell
migration is a syndecan-1 dependent mechanism.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The discovery of interleukin-34 (IL-34) in 2008 upset the functional
biological concepts that had been admitted for many years between
Macrophage Colony Stimulating Factor (M-CSF) and its receptor, the
M-CSF receptor (M-CSFR) [1,2]. LikeM-CSF, IL-34 promotes the survival
and proliferation of monocytes, as well as their differentiation into
macrophages [3]. Macrophages induced by IL-34 have phenotypes and
functions that are similar to those differentiated by M-CSF, as both
cytokines polarize these macrophages into immunosuppressive macro-
phages M2 [4]. In addition, and in association with the Receptor Activa-
tor of Nuclear Factor Kappa-B Ligand (RANKL), IL-34 can replace M-CSF
to induce osteoclast formation by stimulating the proliferation and ad-
hesion of osteoclast precursors [5]. The cytokine also overlaps with theof Medicine, 1 rue Gaston Veil,
+33 240 412 860.
D. Heymann).roles played by M-CSF in inﬂammation in degenerative bone diseases
such as rheumatoid arthritis [6] and periodontal inﬂammation [7].
All these effects are mediated by a cell-surface tyrosine kinase activity
receptor,M-CSFR, encoded by the proto-oncogene c-fms, and also called
c-fms, CD115 or CSF-1R [8]. The homodimeric cytokines M-CSF or IL-34
bind in a close way to the extracellular domain of M-CSFR, but with a
different binding mode [9,10], leading to receptor dimerization and
differential auto-phosphorylation on its eight tyrosine residues [11].
M-CSF/M-CSFR and IL-34/M-CSFR crystals have quite a similar shape,
except a higher stability for the IL-34/M-CSFR complex [12]. Chihara
et al. showed some differences in the kinetics of M-CSFR phosphoryla-
tions and in the nature and intensity of phosphorylated tyrosine resi-
dues after M-CSF or IL-34 binding, which partly explains their ability
to differentially activate the monocyte/macrophage lineage [13].
M-CSF-R knockout mice [14] exhibit a similar but more pronounced
phenotype than op/op mice [15,16]characterised by a more severe
osteopetrosis and reduction of tissue macrophages. This observation
suggested the existence of another ligand for the M-CSFR, and IL-34
was a perfect candidate. Although IL-34 expression under the promoter
of the M-CSF gene rescues the phenotype of op/op mice, the cytokine
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Langerhans cells effectively decrease dramatically in IL-34 knockout
mice, as in M-CSFR deﬁcient mice, while monocytes, lymphoid tissue
macrophages and dendritic cells are not affected. Besides, op/op mice
showquite a conventional development of these cells [18–20]. These re-
sults identify speciﬁc IL-34 activity during embryogenesis and tissue
homeostasis, andmake it possible to better understand the tissue distri-
bution and independent activity of IL-34 [21].
IL-34 is highly expressed in both post-natal and adult brains,
whereas M-CSFR expression, which is maximal in early development,
dramatically decreases in adult brains [22]. High expression of IL-34
despite an almost undetectable expression of its receptor suggests the
existence of other receptors for the cytokine. In spite of overlapping
and complementary activities between M-CSF and IL-34 through
M-CSFR activation, the “M-CSF twin” may also exert speciﬁc functions
independently of this receptor. The present study thus investigates a
new binding mode for IL-34 that may modulate the bioavailability
and/or activities of this cytokine. This paper provides evidence of
syndecan-1 as a new molecular actor in the M-CSF/IL-34/M-CSFR triad
and proposes one explanation for the differential activation of the
M-CSFR observed after M-CSF and IL-34 stimulation.
2. Material and methods
All experiments described in the manuscript were repeated at
least three times in independent experiments and representative
experiments are shown.
2.1. Reagents
Recombinant human Macrophage-Colony Stimulating Factor
(M-CSF), human interleukin-34 (IL-34), human M-CSF receptor
(M-CSFR), mouse IgG1 (control isotype) and antibody anti-human
M-CSFR were obtained from R&D Systems (Abingdon, UK). Diaclone
(Besançon, France) kindly provided the murine B-B4 anti-syndecan
1 (CD138) IgG1 monoclonal antibody. Antibodies directed against
human CD14, human CD200R and human CD86 were purchased
from Biolegend (Saint Quentin en Yvelines, France). Antibodies
directed against human P-M-CSFR, P-Erk1/2, P-mTor, P-Akt and
the total form of proteins were purchased from Cell Signalling
(Ozyme, Saint Quentin Yvelines, France). Anti-β actin and total phos-
phorylated tyrosine antibodies were respectively provided by
Sigma-Aldrich (Saint Quentin Fallavier, France) and Millipore
(Molsheim, France). Anti-receptor protein tyrosine phosphatase
(RPTPβ/ζ, C-19 clone) and HRP-conjugated secondary antibodies
were obtained from Santa-Cruz (CliniSciences, Nanterre, France).
Chondroitin sulphate salts from shark cartilage, heparin, heparan
sulphate salts and chondroitinases ABC were purchased from
Sigma-Aldrich (Saint Quentin Fallavier, France).
2.2. Cell cultures
The cell lines used in the present study were purchased from the
American Tissue Cell Collection (ATCC, Molsheim, France). HEK293
(HEK), osteosarcoma MNNG/HOS (ATCC® Number: CRL-1547™)
(HOS) were cultured in DMEM (Dulbecco's Modiﬁed Eagle's Medium,
Lonza, Levallois-Perret, France) supplemented with 10% foetal bovine
serum (FBS; HyclonePerbio, Bezons, France) and 2 mmol/L of L-gluta-
mine. HL-60, U937, THP-1 and TF-1cell lines were maintained in RPMI
(Roswell Park Memorial Institute, Lonza) supplemented with 10% FBS.
In addition, TF-1 cells were cultured in the presence of 3 ng/mL of
G-M-CSF according to ATCC recommendations. The human U251
glioblastoma cell line was kindly provided by Dr Mylène Dorvillius
(ATLAB Pharma, Nantes, France) and cultured in DMEM supplemented
with 10% FBS.2.3. Cloning of the human M-CSFR gene and cell transfection
The human M-CSFR gene (NM_005211.3) was cloned in a pCDNA3.3
TOPO TA vector (Life Technologies, Villebon sur Yvette, France) from the
cDNA from a healthy donor CD14+. CD14+ cells were initially isolated
from human peripheral blood donors provided by the French blood
bank institute (Etablissement Français du Sang,Nantes, France, authoriza-
tion number: NTS 2000-24), by using MACS microbeads (MiltenyiBiotec,
Germany) as previously described [5]. The RT-PCR product was obtained
using the following primer sequences: Forward 5′-CACCATGGGCCCAGGA
GTTCTGCTGCT-3′ and Reverse 5′-AACTCCTCAGCAGAACTGATAGTTGTTG
GGCTGCA-3′, and fully sequenced to check for the absence of functional
mutations based on the sequences already published in the data bases.
EmbryonicHEK293 cells andosteosarcomaHOS cellswere transfected
as described below with the pCDNA3 empty plasmid or the pCDNA3
plasmid containing the M-CSFR gene. To obtain a polyclonal population
expressing the membrane M-CSFR, 5 × 106 cells were then stained with
phycoerythrin (PE) conjugated antibodies directed against the M-CSFR
and sorted out on a FACSAria III (Beckman Coulter, Villepinte, France).
The cells expressing the M-CSFR were named respectively HEK M-CSFR
and HOS M-CSFR. The cells transfected with the empty pCDNA3 vector
were called HEK Mock and HOS Mock. Erythroblastic TF-1 cells were
transfected using an Amaxa® Cell Line Nucleofector® Kit by Lonza.
Cell sorting was also carried out to isolate M-CSFR expressing cells
(TF-1 M-CSFR).
2.4. RNA isolation and real-time PCR
Total RNA was extracted using NucleoSpin® RNAII (Macherey
Nagel, Duren, Germany) with one stage of DNase I treatment (25
units, 15 min) to prevent genomic contamination. 1 μg of total RNA
was used for ﬁrst strand cDNA synthesis using the ThermoScript
RT-PCR System (Invitrogen). Real-time PCR was performed on 20 ng
of reverse transcribed total RNA (cDNA), 300 nM of primers and 2×
SYBR Green Supermix (Biorad, Marnes-la-Coquette, France). The analy-
siswas performed according to themethod described byVandesompele
et al. [23] using human glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as the invariant control. Standard curves were obtained
using decreasing quantities of cDNA from the U251 cell line to validate
the RPTPβ/ζ primers according to the MIQE guidelines [24]. The sense
and antisense primers used were: RPTPβ/ζ Forward: 5′-GCAGAGCTGT
ACTGTTGACTT-3′, Reverse: 5′-TGTGCTAGCTTAACCCTGCT-3′; GAPDH
Forward: 5′-TGGGTGTGAACCATGAGAAGTATG-3′, Reverse: 5′-GGTG
CAGGAGGCATTGCT-3′.
2.5. M-CSF and IL-34 binding assays
M-CSF and IL-34 were radio-labelled with iodine-125 (125I)
(which has speciﬁc radioactivity of around 2000 cpm/fmol) using the
chloramine T method, as described by Tejedor and Ballesta [25] and
Godard et al.[26]. To determine the ability to bind to the cells of both
cytokines, 1 × 106 cells were incubated with increasing concentrations
of iodinated M-CSF or IL-34 (up to 1 nM) for 1 h at 4 °C. Non-speciﬁc
binding was determined in the presence of 100-fold excess of the
corresponding unlabelled cytokine. Speciﬁc binding was subsequently
obtained by subtraction of this non-speciﬁc binding from the total
binding signal. Regression analysis of the binding data was carried out
using a one-site equilibrium binding equation (GraFit; Erithacus
Software, Staines, U.K.) and data were plotted in the Scatchard
coordinate system. Cross competition binding curves were obtained
by adding simultaneously to the cells increasing amounts of a competi-
tor cytokine together with a ﬁxed, non-saturable concentration of a
labelled cytokine. The inhibition curves obtained were analysed with
an equation for competitive inhibition between two ligands for a com-
mon binding site. Curve ﬁttings were performed using the GraFit data
analysis programme.
Fig. 1. IL-34 andM-CSF differentially activate theM-CSFR. (A)M-CSFR expression on the cellmembraneof human cells analysed byﬂow cytometry. TF-1: erythroblastic leukaemia cell line,
HEK293: embryonary cell line; HOS: osteosarcoma cell line; HL-60, U-937 and THP-1:myeloid leukaemic cell lines; HOSM-CSFR andHEKM-CSFR: HOS andHEK stably overexpressingM-
CSFR; HOSMock and HEKMock: HOS and HEK cell lines transfected with the empty control vector. The isotype IgG1 was used as the control (in grey on the graphs). (B–E)Western blot
investigations of tyrosine phosphorylation patterns ofM-CSFR andErk1/2 phosphorylation after addition of 50, 100 or 200ng/mL of IL-34 orM-CSF for 1 to 30min, inHEKM-CSFR (B), HOS
M-CSFR (C), TF-1M-CSFR (D) and THP-1 cells (E). All experiments were performed three times in independent conditions and a representative set of experiments is shown.
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The SPR experiments were carried out on a BIAcore 2000 biosensor
(BIAcore, Uppsala, Sweden). Recombinant human IL-34 (5 μg/mL,
in 5 mMmaleate buffer pH= 6.2) was covalently linked to the dextran
matrix of a CM5 sensor chip (BIAcore, Uppsala, Sweden), previously
activated with an ethyl (dimethylaminopropyl) carbodiimide/N-
hydroxysuccinimide (EDC/NHS) mixture. Immobilisation levels in the
1300 RU range were then obtained. Residual active groups were
inactivated by injection of ethanolamine 1 M pH= 8.5 for 10 min. The
binding of decreasing concentrations of chondroitin sulphate salts,
heparin or heparan sulphate salts was monitored, from 100 μg/mL and
with a serial dilution of 1:3. Concentrations up to 500 μg/mL were
assessed for the heparin and heparan sulphate. The ﬂow rate was
around 30 μL/min, and the chip was regenerated with 20 mM NaOH
betweeneach cycle. The resulting sensorgramswereﬁtted usingBiaEval
4.1 software.
Cell binding experiments were carried out in the SPRiplex II. The
SPRi biochip-CH (H0550) was activated with an EDC/NHS mixture,and 200 μg/mL IL-34 was spotted on it with a 500 μM tip for 30 min.
The protein binding capacity of the IL-34 was controlled by injections
of 1 and 2 μg/mL of recombinant human M-CSFR on the chip after
each regeneration cycle performed with 10 mM glycine pH = 1.5.
HEK Mock cells (2 × 105 cells/mL) were then injected on to the chip at
20 μL/min for 10 min.
2.7. Flow-cytometry experiments
Membrane expression of the M-CSFR, syndecan-1, CD14, CD220R,
and CD86 was assessed with ﬂow cytometry (Cytomics FC500;
Beckman Coulter). Cells were incubated with PE-conjugated anti-
human M-CSFR antibody or mouse IgG1 as the control for 30 min. For
syndecan-1 expression, the cells were ﬁrst incubated for 90 min at
4 °C with the anti-syndecan-1 B-B4, before incubation with the
PE-conjugated secondary antibody for 60 min. Similar method was
used to analyse CD14, CD220R and CD86 expression. M-CSFR and
syndecan-1 expressions were analysed using the CXP Analysis software
2.2 (Beckman Coulter).
Fig. 2. IL-34 binds toM-CSFR with a high afﬁnity. Increasing concentrations of 125I-labelled IL-34 (IL-34*) or 125I-labelled M-CSF (M-CSF*) were incubated for 60min at 4 °Cwith 106 cells
and bound and unbound fractions were determined as described in paragraph 2.5 of the "Materials and Methods" section. Curve ﬁtting was performed using the GraFit analysis pro-
gramme. Typical curves revealing a speciﬁc binding fraction of iodinated M-CSF on HEK M-CSFR cells (A) and of iodinated IL-34 on HEK M-CSFR (B) and THP-1 cells (C).
Table summarizing the binding mode of M-CSF and IL-34 on the cells of interest (D). These experiments are representative of three times in independent conditions and a representative
experiment is shown.
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The cells were collected in a RIPA buffer (10 mM Tris pH 8, 1 mM
EDTA, 150mMNaCl, 1% NP40, 0.1% SDS containing a cocktail of protease
and phosphatase inhibitors: 1 mM sodium orthovanadate (Na2VO4),
1 mM phenylmethylsulfonyl ﬂuoride (PMSF), 10 mM sodium ﬂuoride
(NaF), 10 mM N-ethylmaleimide (NEM), 2 μg/mL leupeptin and
1 μg/mL pepstatin). The protein concentration was determined using a
BCA (bicinchoninic acid) protein assay (Sigma-Aldrich). 40 μg of total
protein extracts was prepared in a Laemmli buffer (62.5 mM Tris–HCl,
pH6.8, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.001% bromophenol
blue) and then separated by SDS-polyacrylamide gel electrophoresis.
After electrophoretic transfer, the immobilon-P membranes (Millipore,
Molsheim, France) were blotted with the antibodies referenced in the
Reagents section. The membranes were then probed with secondary
antibodies coupled with horseradish peroxidase. Antibody binding
was visualised with a Pierce enhanced chemiluminescence (ECL) kit
(ThermoSientiﬁc, Illkirch, France). The luminescence detected with a
Charge Couple Device (CCD) camera was quantiﬁed using the GeneTools
programme (Syngene, Cambridge, United Kingdom).
2.9. siRNA gene silencer
The syndecan-1 gene expression was knocked down using speciﬁc
human syndecan-1 siRNA (Ambion, France) and the INTERFERin™
transfection reagent (Polyplus transfection, France). 700 × 103 HEK M-
CSFR cells per well were seeded in a 6-well plate 1 day before transfec-
tion. In each well 50 nm siRNA (Syndecan-1 siRNA: ref#s12634 ;
Ambion® Silencer®Negative Control #1: ref#AM4611) duplexes diluted
in serum-free medium were incubated with 2 μL of INTERFERin™ for
30 min at room temperature. The expression of membrane syndecan-1
was measured by ﬂow cytometry. 48 h after the transfection, 50 ng/mLof IL-34 (5 min, 37 °C) was added to the cells and M-CSFR activation
was determined by Western blot as previously described.2.10. M2a macrophage differentiation and cell migration assays
CD14+ monocytes were isolated from peripheral blood of 3 healthy
donors as previously described in paragraph 2.3. For M2a macrophage
differentiation, CD14+ cells were cultured in RPMI (Roswell Park
Memorial Institute medium, Lonza) supplemented with 1% Human
Serum (Invitrogen), 1% penicillin/streptomycin, and 50 ng/mL of IL-4
(R&D System) for 5 days. Half volume of the medium was renewed at
day 2. After the differentiation culture period, M2a adherent cells
were collected by gentle scraping. Their phenotype was analysed by
ﬂow cytometry (CD14low, CD220R+, CD86+) before use in migration
assays. 2 × 105 M2a macrophages or 5 × 105 THP-1 were pre-treated
for 30 min at 37 °C with a blocking anti syndecan-1 antibody (SDC-1
Ab, B-B4) or the corresponding isotype (IgG1 Ab). Cell migration was
then assessed using a 8 μm Boyden chamber (top well) in RPMI 1%
FCS, with or without 100 ng/mL of IL-34 at the bottom well. Cells
migrating at the bottom well were counted after 6 h of culture. Each
experiment was done in triplicate and repeated three times.2.11. Statistical analysis
Results were analysed using a Kruskal–Wallis test was performed
followed by a Dunn's post-hoc between all conditions using GraphPad
InStat v3.02 software. The results of the migration assays are given as
a mean ± SD of three independent experiments done in triplicate.
Results were considered signiﬁcant at p values ≤ 0.05. All Western
blots were performed three or four times in independent experiments
and a representative blot was changed in each ﬁgure.
Fig. 3. A new IL-34 binding independent of the M-CSFR. (A–B) Inhibition binding assays were carried out on HEK M-CSFR cells. After incubation of HEK M-CSFR cells with a saturating
concentration of 125I-labelled IL-34 (IL-34*), increasing doses of unlabelled IL-34 (A) or unlabelled M-CSF (B) were added to the cells. (C) Binding of 125I-labelled IL-34 was assessed by
Scatchard assay on HEK Mock cells which did not express the M-CSFR. (D) Competition assay of 125I-labelled IL-34 with unlabelled IL-34 was performed on HEK Mock cells.
(E) Binding of HEK Mock cells on IL-34 or M-CSF spotted on a chip analysed by surface plasmon resonance. All experiments were repeated three times in independent times.
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3.1. IL-34 and M-CSF induce differential activation of the M-CSFR
We ﬁrst analysed the membrane expression of M-CSFR in various
human cells with ﬂow cytometry. As expected, the HL-60, U937 and
THP-1 myeloid cell lines intrinsically expressed this cytokine receptor,
in contrast to the erythroblastic TF-1, epithelial HEK293 and HOS
osteosarcoma cells which did not express the M-CSFR (Fig. 1A). The
lack of M-CSFR expression by the TF-1, HEK and HOS cells was con-
ﬁrmed by quantitative PCR (data not shown). Marked expression of
the M-CSFR at the cell membrane was observed in M-CSFR transfected
TF-1, HEK and HOS cells (Fig. 1A).
Based on these observations, we investigated the functionality of
the receptor by studying the cell signalling induced by M-CSF and
IL-34, the two identiﬁed ligands of the M-CSFR (Fig. 1B–E). In HEK
M-CSFR cells, both cytokines induced in a dose- (data not shown) andtime-dependent manner the tyrosine 546, 699, 708, 723 and 923 phos-
phorylation of the receptor's intracellular chains with a peak at 5 min
(Fig. 1B). Similarly, M-CSF and IL-34 induced the phosphorylation of
Erk1/2. Compared to M-CSF, IL-34 induced a weaker activation of the
signalling pathway mediated by M-CSFR activation, at the same dose
and time (Fig. 1B). In the HOS M-CSFR cells, high doses of IL-34
(200 ng/mL) appeared more efﬁcient at inducing the phosphorylation
of the M-CSFR compared to M-CSF, unlike low doses of the cytokine
(50 ng/mL) (Fig. 1C). This higher activation of the M-CSFR by IL-34
was also observed with 100 ng/mL of cytokine in the TF-1 M-CSFR
cells as demonstrated by fast and huge phosphorylation levels of the
M-CSFR (Fig. 1D), data in agreement with Chihara et al. [13]. We then
investigated M-CSFR activation in the THP-1 cells which intrinsically
expressed the receptor chains (Fig. 1E). Consistent with the ﬁndings
obtained with the TF-1 M-CSFR cells, the M-CSFR and MAPK down-
stream signalling pathways were more activated by IL-34 than by
M-CSF (Fig. 1E, Supplementary data 1A). Similar results were obtained
Fig. 4. IL-34 binds to chondroitin sulphate but not to heparin/heparan sulphate chains. Interactions between IL-34 and glycosaminoglycans were studied by surface plasmon resonance
technology. Chondroitin sulphate A (A), chondroitin sulphate B (B), chondroitin sulphate C (C), or heparin (D) was injected on immobilised IL-34 using the parameters described in
the “Materials and methods” section.
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that IL-34 and M-CSF differentially activated the M-CSFR signalling
pathway according to the cell type studied.
3.2. IL-34 binds to HEK and HOS cells lacking the M-CSFR
In light of the differential signalling pathway induced by IL-34
and M-CSF, binding assays using 125I-ligands were carried out on the
different cell lines of interest. A saturation binding curve was obtained,
which after Scatchard transformation, made it possible to estimate the
afﬁnity of IL-34 for the membrane M-CSFR. 125I-IL34 bound all cell
lines studied with an equilibrium dissociation constant around 2 nM,
0.55 nM, 1 nM and 0.75 nM for U937, THP-1, HEK M-CSFR and HOS
M-CSFR cells respectively (Fig. 2A–D). As expected, 125I-M-CSF bound
to the HEK M-CSFR and HOS M-CSFR with a similarly high afﬁnity
(Kd = 0.35 nM). These data demonstrated the capacity of IL-34 to
bind with a high afﬁnity to cell lines expressing the M-CSFR (Fig. 2D).
We next assessed the potency of recombinant IL-34 and/orM-CSF to
compete with 125I-IL-34 binding to cell surface receptors (Fig. 3A, B).
The results demonstrated that cold IL-34 and M-CSF differentially
competed with the 125I-IL-34 binding sites expressed in the HEK
M-CSFR, as revealed by the slope factor of the inhibition curves (0.8
and 2 for M-CSF and IL-34 respectively) (Fig. 3A,B). Similar results
were obtained with the HOS M-CSFR cells (data not shown). 125I-IL-34
binding assays were then performed in HEK Mock cells transfected
with the empty control vector that did not express the M-CSFR
(Figs. 1A, 3C). Surprisingly, speciﬁc 125I-IL-34 speciﬁc binding sites
were detected at the surface of the HEK Mock cells (Fig. 3C,D). This
binding was characterised by a lower afﬁnity (Kd = 14.6 nM) than
those observed in the HEK M-CSFR (Fig. 2B). In contrast to 125I-IL-34,
125I-M-CSF did not bind to cells lacking the M-CSFR (Supplementarydata 2). Complementary SPR experiments reinforced these results and
conﬁrmed the ability of the HEK Mock cells to bind to recombinant
IL-34 spotted on a sensorchip, in contrast to recombinant M-CSF, as
measured by the increasing percentage of reﬂectivity (Fig. 3E). The re-
sults clearly demonstrated an additional binding mode for IL-34
independent of the M-CSFR.
3.3. IL-34 binding to chondroitin sulphate chains modulates M-CSFR
activation
As IL-34 bound with a relatively low afﬁnity to cells that did not
express the M-CSFR (HEK Mock and HOS Mock), cell signalling was
further investigated in these cells after stimulation with a high dose of
IL-34 (200 ng/mL). As shown in Supplementary data 3, the proﬁle of
the phosphorylated tyrosines was not modiﬁed after IL-34 stimulation
(Supplementary data 3A) and no modulation of the different signalling
pathways such as mTor, Akt, (Supplementary data 3B), β-catenin, p38
and Erk1/2 (data not shown) was observed in the presence of IL-34.
Consistent with the ability of IL-34 to bind to glycosaminoglycans [27],
we assessed the IL-34 binding to chondroitin sulphate and heparin/hep-
aran sulphate chains by SPR. The SPR sensorgrams revealed a low
afﬁnity binding of the various types of chondroitin sulphate to IL-34,
with a Kd of 132 nM, 775 nM and 16.1 nM for chondroitin sulphates A
(Fig. 4A), B (Fig. 4B) and C (Fig. 4C) respectively. On the contrary,
heparin (Fig. 4D) and heparan sulphate (data not shown) were not
able to bind IL-34, even with high doses of up to 500 μg/mL.
In light of these data, the chondroitin sulphate chainsmay be behind
the IL-34 binding to the HEK Mock and HOS Mock cells, as well as the
differential signalling pathways induced by M-CSF or IL-34 in the HEK
M-CSFR. To explore this hypothesis, HEK M-CSFR cells were then
treated with chondroitinase A, B, C solution (chABC) to abrogate the
Fig. 5. Chondroitin sulphate chains regulate theM-CSFR phosphorylations induced by IL-34. (A) HEKM-CSFR cells were treatedwith amixture of chondroitinases A, B and C for 90min at
37 °C, before addition of 50 ng/mL of M-CSF or IL-34 for 5 min. (B) HEK M-CSFR cells were pre-incubated with 1, 3 or 10 μg/mL of chondroitin sulphate salts for 90 min at 37 °C before
addition of 50 ng/mL of M-CSF or IL-34 for 5 min. The phosphorylation patterns of the M-CSFR and ERK1/2 were assessed by Western blot. Total forms of M-CSFR, ERK1/2 and β-actin
were used as a loading control. Bar graphs show relative densitometric values of pTyr-723 normalised to the M-CSFR. Similar densitometric measurements were obtained for pTyr-746
or pTyr-708, normalised to the M-CSFR or to β-actin. These experiments were performed three times in independent conditions and a representative experiment is shown.
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M-CSF- or IL-34-induced signalling pathways. Consistent with the
results presented in Fig. 1B, theM-CSFRwas less activated after addition
of 50 ng/mL of IL-34 compared to stimulationwith the same dose of M-
CSF, as illustrated by the phosphorylation levels of tyrosines 546, 708
and 723 (Fig. 5A). Interestingly, the chABC treatment markedly
increased the levels of M-CSFR phosphorylations induced by IL-34 as
demonstrated by the phosphorylation levels ofM-CSFR, whereas the re-
sponse induced byM-CSF remained unchanged (Fig. 5A). Similar results
were obtained for ERK1/2. Both cytokines were also pre-incubated with
1, 3 or 10 μg/mLCS salts for 1 h at 37 °C prior to their addition to theHEK
M-CSFR cells. The addition of CS did not modulate the M-CSF-induced
signalling pathway (Fig. 5B). On the contrary, pre-incubation of CS
with IL-34 led to increased phosphorylation of the receptor tyrosines
708 and 723 (Fig. 5B). Overall, these data clearly demonstrated that CS
strongly regulates the biological activities of IL-34.
3.4. IL-34 binding to chondroitin sulphate is independent of the receptor
protein tyrosine phosphatase β/ζ (RPTPβ/ζ)
RPTPβ/ζ, a proteoglycan mainly expressed in the central nervous
system, was recently identiﬁed on the glioblastoma cell line U251 as
another receptor for IL-34 through its CS chains, explaining the role of
the cytokine in brain development [27]. We then analysed RPTPβ/ζ
expression in THP-1, TF-1, HOS Mock and HEK Mock cells. The RPTPβ/
ζ was not expressed at either the transcriptional or the protein levels
in any of these cells in contrast to the U251 cells used as a positivecontrol (Fig. 6). IL-34 binding to the HEK Mock and HOS Mock cells
was consequently independent of RPTPβ/ζ.
3.5. The IL-34-induced migration of myeloid cells is syndecan-1 dependent
Within the proteoglycan families, the syndecans control a lot of
biological functions, such as angiogenesis, cytokine bioavailability, and
cell adhesion/interactions. To investigate the functional involvement
of syndecans in IL-34 biology, syndecans 1, 2 and 4 were individually
overexpressed in the HEK M-CSFR cells and the phosphorylation levels
of theM-CSFR were then analysed in the presence of IL-34. The overex-
pression of syndecan-1 in the HEK M-CSFR cells exacerbated the cell
response to IL-34 (Fig. 7A,B). Indeed, this overexpression induced stron-
ger activation of the M-CSFR when IL-34 was added compared to the
effects in non-transfected cells (NT) or cells transfected with an empty
plasmid (Mock), as shown by the increased phosphorylations of
708 and 723 tyrosines (Fig. 7B). In contrast, the overexpression of
syndecan-2 or -4 did not have any impact on M-CSFR activation by
IL-34 (Supplementary data 4). The addition of a blocking syndecan-1
antibody reduced the IL-34-induced M-CSFR activation as measured
by the levels of 708 and 723 tyrosine phosphorylations in cells overex-
pressing syndecan-1 (Fig. 7C). Anti-syndecan-1 antibody did notmodu-
late by itself the M-CSFR phosphorylation while it upmodulated IL-34
effects on M-CSFR activation in non transfected cells (Fig. 7D). To
conﬁrm the involvement of syndecan-1 in the IL-34 induced signaliza-
tion, the syndecan-1 gene expression was knocked down using speciﬁc
human syndecan-1 siRNA. As expected, syndecan-1 siRNA signiﬁcantly
Fig. 6.HEK,HOS, THP-1 and TF-1 donot express the receptor protein tyrosine phosphatase
RPTPβ/ξ. The expression of the receptor protein tyrosine phosphatase RPTPβ/ξ was
assessed in the different cells used in the study both at the transcriptional level by quan-
titative RT-PCR (A), where expression was normalised against GAPDHmRNA levels, and
at the protein level by Western blot, where β-actin was used as a loading control (B).
These experiments were performed three times in independent conditions and a repre-
sentative experiment is shown.
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by ﬂow cytometry (Fig. 8A). Similarly to the addition of a blocking
syndecan-1 antibody, the knocking down of syndecan-1 upregulated
the M-CSFR phosphorylations (Fig. 8B). Similar results were obtained
for ERK1/2. We then compared the IL-34 dose response on the
M-CSFR phosphorylations in HEK M-CSFR subpopulations expressing
differentially syndecan-1 (Supplementary data 5). The data showed
that IL-34-induced M-CSFR phosphorylations reached a plateau in the
presence of 25 ng/mL for pTyr-708 whereas no plateau was observed
in cells expressing higher syndecan-1 expression even in the presence
of 100 ng/mLof IL-34 (Supplementary data 5). These data demonstrated
that syndecan-1 was able to modulate the biological activities of IL-34
through the M-CSFR.
To elucidate the functional implication of the syndecan-1/IL-34
interactions, we ﬁrst analysed the expression of syndecan-1 in various
cell types (Fig. 9A). Syndecan-1 appears highly expressed by several
cell types with haematopoietic (THP-1), mesenchymal (HOS Mock)
and epithelial (HEK Mock) origin in contrast to U937 and TF-1 cells.
IL-34 signiﬁcantly increased the migration of THP-1 cells compared to
the control (Fig. 9B, p b 0.001). This IL-34-induced THP-1 cell migration
was abolished by the addition of a blocking anti-syndecan-1 antibody.
We then investigated the expression of syndecan-1 by human mono-
cytes/macrophages (Fig. 9C). CD14+ cells expressed a very low level
of syndecan-1 and interestingly, when CD14+ cells were differentiated
toward M2a macrophages (CD14low, CD200R+, CD86+), differentiated
cells highly expressed the syndecan-1 (Fig. 9C). We then investigated
the effects IL-34 on syndecan-1 expressing M2a macrophages. IL-34
signiﬁcantly stimulated the migration of M2a macrophages (Fig. 9C,
p b 0.001). Similarly to the THP-1 cells, the addition of a blocking
anti-syndecan-1 antibody totally inhibited the IL-34-induced M2a
macrophage migration. Anti-syndecan-1 antibody had no effect on cellproliferation or on IL-34-associated monocyte survival (data not
shown). Overall, these investigations demonstrated that IL-34 induced
the migration of myeloid cells in a syndecan-1 dependent manner.
4. Discussion
IL-34 and M-CSF are considered as “twin” cytokines sharing
common M-CSFR chains. However, while both cytokines have some
functional overlaps, they also have speciﬁc activities, especially in the
differentiation and activation of the monocyte/macrophage lineage,
effects in favour of the existence of an additional, unknown receptor
for IL-34 [13,18–20]. Recently, Nandi et al. [27] highlighted an alterna-
tive receptor for IL-34, the receptor protein tyrosine phosphatase β/ζ
(RPTPβ/ζ), known to increase tyrosine phosphorylations of down-
stream proteins such as β-catenin, Src family kinases, focal adhesion
kinase or Erk1/2. The present manuscript characterised a new binding
mode for IL-34 to cells that express neither the M-CSFR, nor the
chondroitin sulphate proteoglycan RPTPβ/ζ. This new IL-34 binding is
dependent on chondroitin sulphate chains, and syndecan-1 was identi-
ﬁed as regulating the IL-34 activation levels of the M-CSFR.
RPTPβ/ζ interacts with IL-34 through its chondroitin sulphate
chains [27]. These authors demonstrated with enzymatic treatment
and CS addition that chondroitin sulphate competed with IL-34 for
binding to the extracellular domain of RPTPβ/ζ, revealing binding
dependence on RPTPβ/ζ chondroitin sulphate chains. Like RPTPβ/ζ,
chondroitin sulphate moieties seem to be a prerequisite for IL-34
binding to syndecan-1. RPTPβ/ζ and syndecan-1 are transmembrane
proteoglycans with common features. Both proteins have glycosami-
noglycans on their ectodomain, and their intracellular C-terminal
moiety interacts with proteins containing the PDZ domain [28,29].
The polymorphism of glycosaminoglycans attached to the protein
core of syndecan-1 is due to different post-translational modiﬁca-
tions and is directly linked to tissue-speciﬁc functions [30]. Thus,
the degree of glycosylation of the extracellular domain explains
the versatility of the syndecan family. Syndecan-1 belongs to a
proteoglycan family including four members: syndecan-1 mainly
expressed in epithelial cells [31], syndecan-2 mainly present in mes-
enchymal cells [32], syndecan-3 mostly found in neuronal and carti-
lage tissues [33] and syndecan-4 which is ubiquitously expressed
[34]. All members of this family have heparan sulphate chains but
only syndecan-1 and syndecan-3 display chondroitin sulphate
chains on their protein core. Syndecan-4 has been also described,
to a lesser extent, in a chondroitin sulphate-associated form [35].
Based on these data, IL-34 binding to the various syndecans must
be considered according to tissue context and, for instance, IL-34
binding to syndecan-3 must not be excluded in the brain, especially
regarding the importance of both IL-34 and syndecan-3 in the neuro-
nal environment.
Proteoglycans are commonly devoted to numerous biological
functions [36] and it is accepted that they control the activities of a lot
of cytokines/growth factorswith orwithout glycosaminoglycan binding
domains such as the heparin binding domain. Thus, the various proteo-
glycans serve as a reservoir for cytokines/growth factors and also
modulate their induced signalling pathways by acting directly on the
cytokine/growth factors-receptor interaction or by the regulation of
cytokine activation and/or turnover [37]. In light of these pleiotropic
activities, glycosaminoglycans may be involved in the sequestration of
IL-34 at the cell membrane as revealed by the chondroitinase treatment
that increased the phosphorylation levels of the M-CSFR induced by
IL-34 (Fig. 5A). Abrogation of membrane chondroitin sulphate chains
may then reduce the trapping of IL-34 in these chains andmay facilitate
IL-34 binding to the M-CSFR (Fig. 10A, B). Similarly, the pre-incubation
of chondroitin sulphate chainswith IL-34 upmodulated the signal trans-
duction through theM-CSFR (Fig. 5B). In this context, soluble chondroi-
tin sulphate chains may act as competitors to their homologous
membrane forms and may limit IL-34 sequestration at the cell surface,
Fig. 7. Syndecan-1 modulates the M-CSFR phosphorylations induced by IL-34. HEK M-CSFR were transiently transfected with a plasmid-encoding human syndecan-1. (A) Syndecan-1
expression analysed by ﬂow cytometry, 48 h after transient transfection. Syndecan-1 expression in Mock M-CSFR transfected with an empty vector of syndecan-1 (empty histogram).
Syndecan-1 overexpressing cells were stimulated with or without 50 ng/mL of IL-34 for 5 min (B) in the presence or absence of 20 μg/mL of syndecan-1 blocking antibody pre-incubated
for 90min (C). Similar experimentswereperformed onHEKM-CSFR (non transfected for syndecan-1)with orwithout 100ng/mLof IL-34 and/or 10 μg/mL of anti-syndecan-1 antibody for
1 and 5min (D). M-CSFR- and ERK1/2-phosphorylationswere assessed byWestern blot, with theM-CSFR, ERK1/2 total forms of and GAPDH as a loading control. Bar graphs show relative
densitometric values of pTyr-723 and pTyr-708 normalised to the M-CSFR. These experiments were performed four times in independent conditions and a representative
experiment is shown.
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soluble chondroitin sulphates compete with IL-34 for binding to the
extracellular domain of RPTPβ/ζ [27], in contrast to the extracellular
domain of M-CSFR (present data).
The co-receptor functions of proteoglycans are well illustrated by
their interaction with the ﬁbroblast growth factor and its receptor
(FGF/FGFR). The FGF was the ﬁrst growth factor identiﬁed as being
dependent on heparin/heparan sulphate chains for its binding to the
FGFR. The ternary complex FGF/FGFR/proteoglycans formed directly
modulates the signalling pathways induced by the growth factor [38].
The co-receptor role of glycosaminoglycans has then also been demon-
strated for epidermal growth factor (EGF) [39], hepatocyte growth fac-
tor (HGF) [40], vascular endothelial growth factor (VEGF) [41], Wnt
factors [42] or members of the transforming growth factors (TGFs)
[43]. In these cases, syndecan-1, via its heparan sulphate chains, acts
as a co-receptor for these growth factors. Our present results suggest
that syndecan-1 may also act as a modulator for the tyrosine kinase
M-CSFR, but through its chondroitin sulphate chains. Syndecan-1exhibits a stimulatory or inhibitory role, probably depending on its ex-
pression level. Thus, a low/moderate level of syndecan-1 may seques-
trate IL-34 at the cell surface through its chondroitin sulphate chains,
limiting the interaction between IL-34 and the M-CSFR (Fig. 8D). The
overexpression of syndecan-1 induced signiﬁcant phosphorylation of
theM-CSFR, reinforced by the presence of IL-34. Interestingly, the over-
expression of syndecan-1modulate the pTyr723 of theM-CSFR thatwas
already associated with the activation of speciﬁc signalling pathways
(PI3K, Rho GTPases, paxilline, SFKs/Pyk2, etc) involved in cell migration
[2,44]. In contrast, a blocking anti-syndecan-1 antibody signiﬁcantly re-
duced the effects of IL-34. The enhanced activation by syndecan-1 may
be explained by the membrane proximity between the M-CSFR and
syndecan-1, the biodistribution of syndecan-1 at the cell membrane
being directly related to its expression level. IL-34 stimulation did not
induce detectable signalling pathways (Supplementary data 2) in
MOCK cells expressing syndecan-1 but not the M-CSFR and the
RPTPβ/ζ. These ﬁndings strengthen the hypothesis of a regulator for
syndecan-1 on IL-34 signalling through the M-CSFR. Previous works
Fig. 8. Syndecan-1 siRNA increases the phosphorylation M-CSFR induced by IL-34. The syndecan-1 gene expression was knocked down using speciﬁc human syndecan-1 siRNA.
(A) Syndecan-1 expression analysed by ﬂow cytometry, 48 h after siRNA transfection. (B) Syndecan-1 knocked down cells were stimulated with or without 50 ng/mL of IL-34 for
5 min and M-CSFR-, ERK1/2-phosphorylations were assessed by Western blot, with the total forms of M-CSFR and ERK1/2 as a loading control. Bar graphs show relative densitometric
values of pTyr-723 normalised to the M-CSFR. Similar densitometric measurements were obtained for pTyr-708, normalised to the M-CSFR or to GAPDH. A representative experiment
out of three independent experiments is shown.
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the syndecan extracellular domains, such as integrins and tyrosine ki-
nase receptors. Thus, αvβ3 integrin and insulin-like growth factor 1 re-
ceptor (IGF1R) are captured by syndecan-1 to form a ternary receptor
mainly expressed on tumour cells and endothelial cells and involved
in the angiogenesis process [45]. Further investigations will be neces-
sary to investigate the potential role of syndecan-1 in the IL-34 trapping.
Syndecan-1 is implicated in the control of cellular chemoattraction.
Indeed, membrane proteoglycans, including the syndecan family, are
responsible of a chemotactif gradient on endothelial cells linked to the
adherence and migration of numerous circulating cells such as neutro-
phils [46]. Syndecan-1 mediated the osteoprotegerin-induced chemo-
taxis in human peripheral blood monocytes and may control by this
mechanism, the inﬂammatory process and the bone remodelling [47,
48]. Proteoglycans like syndecan-1 contributes to the control of the
pathogenesis of osteolysis [49,50]. Thus, tumour-derived syndecan-1
is associated a crosstalkwith bone and an increase of osteoclastogenesis
[49,50]. By interacting with syndecan-1, IL-34 may have a double in-
volvement in osteoclastogenesis, by inducing the migration of myeloid
osteoclast precursors expressing syndecan-1 and by substituting for
M-CSF in RANKL-induced osteoclastogenesis [5]. In addition, IL-34 was
already shown to drives in vitro the polarization ofmacrophages toward
anM2 immunosuppressive phenotype and function [4]. Several reports
have described the accumulation of TAMs in tissue during the tumour
development and TAMs are considered to facilitate the metastatic
process [51]. We showed that syndecan-1 controls the IL-34-induced
M2 macrophage migration (Fig. 9), which can be related to the role ofIL-34 in the biology of M2 macrophages [4]. The increased expression
of syndecan-1 by macrophages was already observed during the mye-
loid differentiation and during the inﬂammatory process [52,53].
These authors found a link between macrophage motility and the ex-
pression level of syndecan-1.
Syndecan-1 can now be added to the list of key regulators of IL-34
activities in addition to M-CSFR and RPTPβ/ζ, but not of M-CSF. By con-
trolling IL-34 bioavailability, by modulating the recruitment of M-CSFR
chains or the afﬁnity of IL-34 to the receptor chains, and/or by acting
as a regulator signalling of the M-CSFR, syndecan-1 may play a part in
the role of IL-34 in development [22], bone [5] and inﬂammatory dis-
eases [6]. Consequently, new therapies targeting the IL-34/M-CSFR
axis must now take into account the existence of other receptors for
the cytokine.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.01.023.
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